Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial
- 28 July 2017
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 37 (6) , 548-558
Abstract
Purpose The purpose of this study was to evaluate engraftment and adverse events with a conditioning and prophylactic regimen intended to achieve high rates of engraftment with minimal graft-versus-host disease (GVHD) in allogeneic transplantation for chronic granulomatous disease in a single center. Methods Forty patients, 37 male, with chronic granulomatous disease were transplanted. Transplant products were matched sibling peripheral blood stem cells (PBSCs) in four and matched unrelated donor (MUD) bone marrow in three, and one patient received mismatched unrelated PBSCs. Thirty-two patients received MUD PBSCs. All patients received a conditioning regimen of busulfan/alemtuzumab (with low-dose total body irradiation for MUD recipients) with sirolimus graft-versus-host disease prophylaxis. Results Engraftment occured in 38/40 recipients (95%). Acute or chronic GVHD occurred in 18 (45%) and 5 (12.5%), respectively, with 6 episodes of grades III–IV and/or steroid refractory GVHD. Overall survival was 33/40 (82.5%) and event-free survival was 30/40 (80%). Successful engraftment was associated with myeloid and NK cell, but not CD3+ chimerism. Myeloid engraftment was greater than 70% in 30/32 recipients at mean follow-up of 3.4 years. Evidence of persistent immunodeficiency was not seen in successful transplants. Attempts to rescue failed or poorly functioning grafts were associated with unacceptable morbidity and mortality. Conclusions A reduced-intensity allogeneic transplant protocol based on alemtuzumab and busulfan with sirolimus GVHD prophylaxis produced high rates of successful engraftment and minimal regimen-related toxicity. Prolonged clinical follow-up has confirmed its efficacy in ameliorating CGD-related disease. Outcomes were not acceptable with donor cell infusion rescue of cause with poor graft function.Keywords
This publication has 27 references indexed in Scilit:
- Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experienceBlood, 2016
- Reduced‐intensity conditioning for hematopoietic cell transplantation of chronic granulomatous diseasePediatric Blood & Cancer, 2014
- Chronic granulomatous disease - haematopoietic stem cell transplantation versus conventional treatmentActa Paediatrica, 2013
- Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantationLeukemia, 2011
- Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipientsPediatric Transplantation, 2011
- Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionBlood, 2010
- Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failureClinical Transplantation, 2010
- NK Cells Delay Allograft Rejection in Lymphopenic Hosts by Downregulating the Homeostatic Proliferation of CD8+ T CellsThe Journal of Immunology, 2010
- Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseNew England Journal of Medicine, 2009
- Low-Dose Radiation Plus Rapamycin Promotes Long-Term Bone Marrow ChimerismTransplantation, 2005